27th August 2019 – Global Targeted
DNA/RNA Sequencing Market is expected to reach USD 15.9 billion by
2025. Targeted sequencing is a technique in which a subgroup of genes or
regions of the genome are isolated and sequenced. The technique enables
researchers to analyze data, focus time, and expenses on target areas of
interest and allows sequencing at advanced exposure levels. Targeted gene
sequencing panels are important tools for analyzing precise mutations in a
specified sample.
Next-generation sequencing (NGS) is a
technique that plays important role in targeted sequencing and offers the
resolution, scalability, and speed to assess targeted genes of interest.
Multiple genes can be evaluated at a time by reducing cost and saving time.
Moreover, targeted gene sequencing makes the study easier and produces smaller
and manageable data set. The Targeted DNA/RNA Sequencing Market is estimated to
grow at a significant CAGR over the future period as the scope and its
applications are rising enormously across the globe.
Targeted DNA/RNA Sequencing Market is
segmented based on method, types, applications, end users, and region. Amplicon
generation and target enrichment are the two important methods used for
Targeted DNA/RNA Sequencing that could be explored in forecast period.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/targeted-dna-rna-sequencing-market/request-sample
AnRNA-based Targeted Sequencing and
DNA-based Targeted Sequencing are the types of Targeted DNA/RNA Sequencing that
could be explored in the foremost period. RNA-based Targeted Sequencing is a
technique for sequencing and selecting specific pathways or transcripts of
interest of gene expression microarray. The technique is used for measuring
transcripts of interest for analyzing splice junction, differential expression,
cSNPs, allele-specific expression, isoforms, and gene-fusions.
This method can be qualitative or
quantitative. The market may be categorized based on applications like drug
discovery, human biomedical research, plant & animal sciences, and others.
Pharma & biotech entities, academic research, hospitals & clinics, and
other end users could be explored in Targeted DNA/RNA Sequencing in the future
period.
Globally, North America accounted for
the largest market share of Targeted DNA/RNA Sequencing and is estimated to
lead the overall market in the coming years. The reason behind the overall
market growth could be permission from NIH to allow target-sequencing study in
the region, existence of active governing bodies to assess the sequencing-based
genetic tests, and presence of developed research and development sector with
enhanced technology. The United States is a major consumer of Targeted DNA/RNA
Sequencing in the coming years.
Instead, Europe and the Asia Pacific are
also estimated to have a positive influence on the future growth. Europe is the
second largest region with significant market share. However, Asia Pacific is
estimated to grow at fastest pace with the highest CAGR in the foremost period.
The aspects that may be ascribed to the growth comprise low price of NGS-based
tests in China in comparison with the U.S., government initiative for
developing NGS platform as regarded by regulatory agencies, and developing
research and development sector. The developing countries like China, Japan,
and India are the major consumers of Targeted DNA/RNA Sequencing in the region.
The key players of Targeted DNA/RNA
Sequencing industry are Macrogen, Inc., Illumina, Inc., Genomatix GmbH,
Hoffmann-La Roche Ltd., PierianDx, Agilent Technologies, Integrated DNA
Technologies, Inc., Agilent Technologies, Bio-Rad Laboratories, GATC Biotech
Ag, Pacific Biosciences of California, and Oxford Nanopore Technologies. These
players are concentrating on inorganic growth to sustain themselves amongst
fierce competition. As companies all over the world have to believe that
alliance with a market would permit them proportional market existence and authority
to declare the leadership position.
For More Details, Visit @ http://www.millioninsights.com
No comments:
Post a Comment